Compare FDX & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FDX | SNY |
|---|---|---|
| Founded | 1971 | 1994 |
| Country | United States | France |
| Employees | N/A | 74846 |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.6B | 104.5B |
| IPO Year | 1997 | N/A |
| Metric | FDX | SNY |
|---|---|---|
| Price | $319.34 | $42.34 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 5 |
| Target Price | ★ $376.67 | $58.00 |
| AVG Volume (30 Days) | 2.0M | ★ 3.5M |
| Earning Date | 03-19-2026 | 04-23-2026 |
| Dividend Yield | 1.49% | ★ 3.47% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 11.91 | N/A |
| Revenue | ★ $65,450,000,000.00 | N/A |
| Revenue This Year | $7.43 | $3.49 |
| Revenue Next Year | $4.96 | $6.10 |
| P/E Ratio | $27.62 | ★ $6.14 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $216.10 | $40.89 |
| 52 Week High | $413.87 | $52.68 |
| Indicator | FDX | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 37.51 | 43.39 |
| Support Level | $299.25 | $42.30 |
| Resistance Level | $318.83 | $48.76 |
| Average True Range (ATR) | 10.41 | 0.73 |
| MACD | -0.21 | -0.15 |
| Stochastic Oscillator | 29.00 | 35.86 |
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In fiscal 2025, the firm's Federal Express segment—which houses the core package delivery operations—made up 86% of total revenue, with 10% coming from FedEx Freight, its asset-based less-than-truckload shipping segment. The remainder came from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016, boosting its presence across Europe. TNT was previously the fourth-largest global parcel delivery provider.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.